摘要
目的:明确精神分裂症患者复发风险感知的主要内容,探讨其风险感知的特征与变化.方法:采用现象学研究方法,对首次发病、首次复发和多次复发的精神分裂症患者进行半结构式深入访谈,共计纳入23例符合美国精神障碍诊断与统计手册第5版(DSM-5)精神分裂症诊断标准的门诊和住院患者,所有患者PANSS得分均低于60分.所有资料按照定性研究中的Colaizzi分析法进行整理与分析.结果:精神分裂症患者复发风险感知包括4个主题和11个亚主题:易感性(整体认识片面模糊、从乐观到客观的转变),预警症状(动态提升、家属帮助患者识别),危险因素(缺乏了解、心理社会因素与复发的关系、服药与复发关系的动态认识)和后果风险感知(照护负担和经济负担、社会功能受损及适应不良、影响公共安全、自身健康风险).结论:精神分裂症患者复发风险的感知内容较为丰富,且整体复发风险感知水平较低.
Abstract
Objective:To elucidate the primary elements pertaining to the perception of relapse risk and to in-vestigate the characteristics and alterations of perception of the risk of recurrence in patients with schizophrenia.Methods:By using the method of phenomenological study,semi-structured in-depth interviews were conducted among schizophrenic patients with first onset,first recurrence and multiple recurrences.Twenty-three 23 outpatient and inpatient cases that met the criteria of the Diagnostic and Statistical Manual of Mental Disorders,Fifth Edition(DSM-5)were included,and all patients had PANSS scores below 60.The interview data were collated and analyzed according to Colaizzi analysis.Results:The perception of recurrence risk in patients with schizophrenia en-compassed 4 major themes and 11 sub-themes,namely susceptibility(limited overall understanding,transition from optimism to objectivity),detection of early warning symptoms(dynamic escalation,assistance from family mem-bers in identification),understanding risk factors(lack of understanding,the relationship between psychosocial fac-tors and relapse,dynamic understanding of medication-relapse relationship),and apprehension of the consequences of recurrence(care burden and financial constraints,impaired social functioning and maladjustment,impact on pub-lic safety,personal health risks).Conclusion:The content of risk perception of recurrence in patients with schizo-phrenia is relatively substantial.The overall level of risk perception of recurrence in patients with schizophrenia is low.
基金项目
国家自然科学基金面上项目(72074063)
教育部人文社会科学研究项目(21YJCZH145)
黑龙江省教育科学规划课题重点项目(GJB1422788)
大庆市科技局项目(zdy-2021-85)
哈尔滨医科大学创新基金(2018-KYYWF-0555)
维普
万方数据